Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Core Viewpoint - Citius Pharmaceuticals is focused on the launch of its first FDA-approved product, LYMPHIR, while actively seeking financing and strategic partnerships to support its commercialization efforts [2][4]. Financial Results - For the fiscal quarter ended March 31, 2025, Citius Pharmaceuticals reported a net loss of $11.5 million, or ($1.27) per share, compared to a net loss of $8.5 million, or ($1.34) per share, for the same quarter in 2024 [14][22]. - The company incurred a net loss of $21.8 million for the six months ended March 31, 2025, compared to a net loss of $17.8 million for the same period in 2024 [15][22]. - Research and development (R&D) expenses for the quarter were $3.8 million, up from $3.6 million in the same quarter of 2024, while total R&D expenses for the six months were $5.9 million, down from $6.3 million in the prior year [8][15]. - General and administrative (G&A) expenses increased to $4.8 million for the quarter, compared to $4.3 million in the same quarter of 2024, and totaled $10.2 million for the six months, up from $7.9 million [11][12]. Liquidity and Capital - As of March 31, 2025, the company had $26,410 in cash and cash equivalents and had raised $6 million from equity issuances during the six months [5][6]. - The company closed a registered direct offering on April 2, 2025, generating approximately $1.735 million in net proceeds [5]. - Citius Pharma plans to continue funding Citius Oncology until adequate capital is raised or revenue is generated from LYMPHIR sales [7]. Research and Development Focus - The company is preparing a submission to the FDA for its Mino-Lok program, which is a key step toward a future New Drug Application (NDA) [3]. - R&D expenses related to LYMPHIR increased to $5.3 million for the six months ended March 31, 2025, compared to $3.2 million for the same period in 2024, primarily due to costs associated with drug substance batches [9][10]. Company Overview - Citius Pharmaceuticals is dedicated to developing first-in-class critical care products, with LYMPHIR being a targeted immunotherapy approved by the FDA for cutaneous T-cell lymphoma [16]. - The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief [16].